ACA
FATE icon

Affinity Capital Advisors’s Fate Therapeutics FATE Stock Holding History

Affinity Capital Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,410
Closed -$287K – 111
2022
Q1 		$287K Buy
7,410
+51
+0.7% +$1.98K 0.09% 91
2021
Q4 		$431K Buy
7,359
+20
+0.3% +$1.13K 0.13% 76
2021
Q3 		$435K Hold
7,339
– – 0.15% 74
2021
Q2 		$637K Hold
7,339
– – 0.22% 62
2021
Q1 		$605K Hold
7,339
– – 0.22% 59
2020
Q4 		$667K Sell
7,339
-730
-9% -$45.3K 0.27% 54
2020
Q3 		$323K Sell
8,069
-935
-10% -$32.6K 0.18% 72
2020
Q2 		$309K Hold
9,004
– – 0.2% 68
2020
Q1 		$282K Sell
9,004
-3,355
-27% -$84.8K 0.21% 74
2019
Q4 		$242K Buy
+12,359
New +$196K 0.16% 98

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Affinity Capital Advisors's FATE Position: Q2 2022 in Review

Affinity Capital Advisors sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 7,410 shares — an estimated $287K sold.

Affinity Capital Advisors first reported a position in FATE in Q4 2019 and held it in 10 quarters. The position peaked at $667K in Q4 2020. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Affinity Capital Advisors reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Affinity Capital Advisors sold 7,410 Fate Therapeutics shares in Q2 2022, an estimated $287K.
  • Affinity Capital Advisors first reported a position in Fate Therapeutics in Q4 2019 and held it in 10 quarters.
  • Affinity Capital Advisors's Fate Therapeutics position peaked at $667K in Q4 2020.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Affinity Capital Advisors's 13F filing for Q2 2022, filed 11 Jul 2022.